- Foghorn Therapeutics Provides First Quarter 2024 Financial and Corporate Update
- Foghorn Therapeutics Strengthens Financial Leadership with Appointment of Kristian Humer as Chief Financial Officer
- Foghorn Therapeutics Presents New Preclinical Data on Potential First-in-Class BRM Selective Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Oncology Programs
- Foghorn Therapeutics to Participate in Needham’s 23rd Annual Virtual Healthcare Conference
- Foghorn to Host Conference Call and Webcast on Pipeline of Potential First-in-Class Medicines in Conjunction with the 2024 AACR Annual Meeting
- Foghorn Therapeutics Provides Financial Update for 2023 and 2024 Strategic Outlook
- Foghorn Therapeutics to Present New Preclinical Data at 2024 AACR Annual Meeting, Reflecting Advances with Multiple Potential First-in-Class Medicines, including the Selective Inhibitor of BRM, FHD-909
- Foghorn Therapeutics to Participate in Cowen’s 44th Annual Health Care Conference
- Foghorn Provides Pipeline Update on FHD-909 BRM Selective Inhibitor
- Foghorn Therapeutics Highlights Clinical Program Updates and Research Progress and Provides Strategic Objectives for 2024
More ▼
Key statistics
On Friday, Foghorn Therapeutics Inc. (FHTX:NMQ) closed at 5.51, 104.07% above the 52 week low of 2.70 set on Feb 05, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 5.86 |
---|---|
High | 6.02 |
Low | 5.47 |
Bid | 5.51 |
Offer | 6.29 |
Previous close | 5.81 |
Average volume | 72.94k |
---|---|
Shares outstanding | 42.59m |
Free float | 32.03m |
P/E (TTM) | -- |
Market cap | 234.65m USD |
EPS (TTM) | -2.21 USD |
Data delayed at least 15 minutes, as of May 17 2024 21:00 BST.
More ▼